Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasis–specific targets in a patient with small intestinal neuroendocrine cancer

Abstract

Genomic analysis of a patients' tumor is the cornerstone of precision oncology, but it doesn't address whether metastases should be treated differently. Here we tested whether comparative scRNA-seq of a primary small intestinal neuroendocrine tumor to a matched liver metastasis could guide treatment of a patients' metastatic disease. Following surgery, the patient was put on maintenance treatment with a somatostatin analog. However, the scRNA-seq analysis revealed that the neuroendocrine epithelial cells in the liver metastasis were less differentiated and expressed relatively little SSTR2, the predominant somatostatin receptor. There were also differences in the tumor microenvironments. RNA expression of vascular endothelial growth factors was higher in the primary tumor cells, reflected by an increased number of endothelial cells. Interestingly, vascular expression of the major VEGF receptors was considerably higher in the liver metastasis, indicating that the metastatic vasculature may be primed for expansion and susceptible to treatment with angiogenesis inhibitors. The patient eventually progressed on sandostatin and although consideration was given to adding an angiogenesis inhibitor to her regimen, her disease progression involved non-liver metastases which had not been characterized. Although in this specific case comparative scRNA-seq did not alter treatment, its potential to help guide therapy of metastatic disease was clearly demonstrated.

Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient

“…In the future, integrating additional assays such as the assessment of ESR1 methylation status, single-cell RNA sequencing (scRNA-seq), and multiplex proteomics as well as characterizing the circulating tumor microenvironment could all provide an even deeper characterization of a patient's tumor, its evolution, and response to therapy ( Goon et al 2009 ; Chung et al 2017 ; Mastoraki et al 2018 ; Jackson et al 2020 ; Rao et al 2020 ). In addition, recent studies have investigated the biological features of cfDNA, such as nucleosome positioning, fragment size analysis, and copy-number alteration analysis as a measure for disease outcome ( Snyder et al 2016 ; Mouliere et al 2018 ; Paymaneh et al 2018 ).…”

Dissecting the role of cancer‐associated fibroblast‐derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single‐cell transcriptomic study

“…14 single‐cell sequencing datasets were collected as follows: basal cell carcinoma (BCC_GSE123813), bladder urothelial carcinoma (BLCA_GSE130001), breast cancer (BRCA_GSE114727), cholangiocarcinoma (CHOL_GSE125449), colorectal cancer (CRC_GSE146771), liver hepatocellular carcinoma (LIHC_GSE125449), kidney renal clear cell carcinoma (KIRC_GSE111360), head and neck squamous cell carcinoma (HNSC_GSE103322), neuroendocrine tumor (NET_GSE140312), stomach adenocarcinoma (STAD_GSE134520), skin cutaneous melanoma (SKCM_GSE123139), pancreatic adenocarcinoma (PAAD_CRA001160), ovarian serous cystadenocarcinoma (OV_GSE118828) and non‐small cell lung cancer (NSCLC_GSE131907) (Table S7 ). 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 The global‐scaling normalization method was applied, and the cells were clustered using the uniform manifold approximation and projection method and annotated.…”

Deciphering endothelial heterogeneity in health and disease at single-cell resolution: progress and perspectives

“…Dimensionality reduction and clustering analysis allowed the comparison of EC populations in disease samples. First, a change of the relative proportion of ECs compared to other cell types has been noted in some diseases (Figure 3), with for example fewer ECs detected in metastasis compared to primary tumours, 85 while more ECs have been observed in Alzheimer's disease vs. control samples. 64 Within the EC population, a change in the proportion of EC subtypes corresponds to a second level of heterogeneity observed in disease (Figure 3).…”